Proposition 14 passed by 51.09% to 48.91%, a far cry from 2004. Twenty years and many billions of dollars later, CIRM-funded ...
Any plan to keep our companies at home? 3 Hori7on to release new single on Nov. 3 ...
Prescribed by prime time ...
Prime Medicine, Inc. has recently entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMS) to develop and commercialize multiple prime edited ex vivo ...
Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Week 4 is in the books and oh my there's a lot of panic on these fantasy streets. Scott Pianowski joins Matt Harmon for ...
2d
BMO Capital analyst Kostas Biliouris has reiterated their bullish stance on PRME stock, giving a Buy rating yesterday. Kostas Biliouris has ...
Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY. The collaboration ...
Under the terms of the deal announced yesterday (30 September), Massachusetts-based Prime Medicine will design gene editing ...
On Monday, Prime Medicine Inc (PRME) stock saw a modest uptick, ending the day at $3.87 which represents a slight increase of $0.41 or 11.85% from the prior close of $3.46. The stock opened at $4.23 ...
Prime Medicine Inc. has announced its plans to strategically focus its efforts on a set of high value programs as it advances its pipeline of next-generation gene editing therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback